Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older-Reference-Cited by-同舟云学术

Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older

Published:2021-02 Issue:8 Volume:39 Page:1339-1348
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Winokur Patricia^ORCID,El Sahly Hana M.,Mulligan Mark J.,Frey Sharon E.,Rupp Richard,Anderson Evan J.^ORCID,Edwards Kathryn M.,Bernstein David I.,Schmader Kenneth,Jackson Lisa A.,Chen Wilbur H.^ORCID,Hill Heather,Bellamy Abigail

Funder

Institute of Clinical and Translational Sciences

National Center for Advancing Translational Sciences

Office of Extramural Research, National Institutes of Health

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference51 articles.

1. Human infection with a novel avian-origin influenza A (H7N9) virus;Gao;N Engl J Med.,2013

2. WHO. Avian and other zoonotic influenza. 2018.

3. Centers for Disease Control and Prevention. 2016, November 3.

4. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus;Stevens;Science,2006

5. Two Outbreak Sources of Influenza A (H7N9) Viruses Have Been Established in China;Wang;J Virol.,2016

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity and safety of varying dosages of a fifth-wave influenza A/H7N9 inactivated vaccine given with and without AS03 adjuvant in healthy adults;Vaccine;2024-01

2. Influenza vaccines: where we are, where we are going;Current Opinion in Pediatrics;2022-01-15